Eldelumab

Drug Profile

Eldelumab

Alternative Names: Anti-CXCL10 antibody; Anti-IP10 antibody; BMS-936557; MDX-1100

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex
  • Class Antirheumatics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Crohn's disease; Ulcerative colitis
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Spinal cord injuries

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Russia, Ukraine, Poland, Romania, Mexico, Latvia, Mexico, Czech Republic, France, Netherlands, Hungary, Germany, Italy, Belgium, South Africa, Canada, Australia, Brazil, Austria, USA (IV)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Crohn's disease (Treatment-experienced) in Poland, Israel, France, Belgium, Hungary, USA, Puerto Rico and South Africa (IV)
  • 01 Dec 2014 Bristol-Myers Squibb completes a phase II trial in Crohn's disease in USA, Belgium, France, Hungary, Israel, Poland, Puerto Rico and South Africa (NCT01466374)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top